dalteparin has been researched along with Chronic Illness in 23 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 77-year-old man developed chronic disseminated intravascular coagulation (DIC) after surgical repair of a large infrarenal aortic aneurysm." | 5.31 | Chronic disseminated intravascular coagulation after surgery for abdominal aortic aneurysm: clinical and haemostatic response to dalteparin. ( Awad, R; Cummins, D; Hunt, BJ; Maddox, A; Segal, H, 2001) |
| "We evaluated the hypothesis that a relationship exists between inflammation and the outcome of pharmaceutical cardioversion with amiodarone in recent onset atrial fibrillation." | 3.74 | Interleukin-2 serum levels variations in recent onset atrial fibrillation are related with cardioversion outcome. ( Dragomanovits, S; Kalogeropoulos, AS; Kremastinos, DT; Papathanasiou, S; Rigopoulos, AG; Rizos, I; Sakadakis, EA; Tsiodras, S, 2007) |
| "In 256 patients participating in the FRISC trial, evaluating the effects of dalteparin (a low molecular weight heparin) in unstable angina or non-Q wave myocardial infarction, Chlamydia pneumoniae IgA antibody titres and levels of fibrinogen, C-reactive protein and troponin T were determined at inclusion." | 3.70 | Increased fibrinogen levels are associated with persistent Chlamydia pneumoniae infection in unstable coronary artery disease. ( Gnarpe, H; Gnarpe, J; Lindahl, B; Siegbahn, A; Toss, H; Wallentin, L, 1998) |
| "A total of 284 patients with venous ulcers were recruited in a 4-year period." | 2.80 | Low molecular weight heparin improves healing of chronic venous ulcers especially in the elderly. ( Amato, B; Buffone, G; de Franciscis, S; Molinari, V; Montemurro, R; Perri, P; Serra, R; Stillitano, DM, 2015) |
| "This was a randomized, standard treatment-controlled, 2-center pilot trial of 102 patients (52 receiving adjunctive therapy with enoxaparin at a dosage of 1." | 2.72 | Adjunctive therapy with low-molecular-weight heparin in patients with chronic heart failure secondary to dilated cardiomyopathy: one-year follow-up results of the randomized trial. ( Lekston, A; Nowak, J; Nowalany-Kozielska, E; Poloński, L; Szyguła-Jurkiewicz, B; Trzeciak, P; Wilczek, K; Wodniecki, J; Wojnicz, R; Zembala, M, 2006) |
| "Depression is one of the most prevalent challenges of mental conditions." | 1.42 | The role of hepcidin in chronic mild stress-induced depression. ( Barati, M; Farajdokht, F; Mehrpouya, S; Nahavandi, A; Soleimani, M, 2015) |
| "Subjects with ESRD had an approximately 50% greater anticoagulant effect, determined by thrombin generation time prolongation, than controls at antifactor Xa activity concentrations of 0." | 1.32 | Enhanced anticoagulant activity of enoxaparin in patients with ESRD as measured by thrombin generation time. ( Brophy, DF; Carr, ME; Gehr, TW; Martin, EJ, 2004) |
| "Proteinuria was determined at regular intervals." | 1.31 | Treatment of chronic renal allograft rejection in rats with a low-molecular-weight heparin (reviparin). ( Back, WE; Braun, C; Fang, L; Herr, D; Laux, V; Rohmeiss, P; Schaub, M; Schnuelle, P; Schultz, M; van der Woude, FJ, 2001) |
| "A 77-year-old man developed chronic disseminated intravascular coagulation (DIC) after surgical repair of a large infrarenal aortic aneurysm." | 1.31 | Chronic disseminated intravascular coagulation after surgery for abdominal aortic aneurysm: clinical and haemostatic response to dalteparin. ( Awad, R; Cummins, D; Hunt, BJ; Maddox, A; Segal, H, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (17.39) | 18.2507 |
| 2000's | 11 (47.83) | 29.6817 |
| 2010's | 8 (34.78) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Serra, R | 1 |
| Buffone, G | 1 |
| Molinari, V | 1 |
| Montemurro, R | 1 |
| Perri, P | 1 |
| Stillitano, DM | 1 |
| Amato, B | 1 |
| de Franciscis, S | 1 |
| Asero, R | 1 |
| Tedeschi, A | 1 |
| Cugno, M | 1 |
| Timofeeva, AV | 1 |
| Dobrotvorskaia, TE | 1 |
| Dolgov, VV | 1 |
| Arifullin, ShS | 1 |
| Chazova, IE | 1 |
| Panchenko, EP | 1 |
| Dobrovol'skiĭ, AB | 1 |
| Nakonechnikov, SN | 1 |
| Titaeva, EV | 1 |
| Baklanova, NA | 1 |
| Belenkov, IuN | 1 |
| Duan, S | 1 |
| Wu, S | 1 |
| Chen, P | 1 |
| Ottani, F | 1 |
| Ferrini, D | 1 |
| Di Pasquale, G | 1 |
| Galvani, M | 1 |
| McKeage, K | 1 |
| Keating, GM | 1 |
| Christidou, FN | 1 |
| Frangia, TK | 1 |
| Bamichas, GI | 1 |
| Gionanlis, LC | 1 |
| Natse, TA | 1 |
| Georgoulis, IE | 1 |
| Sombolos, KI | 1 |
| Ahmed, I | 1 |
| Gertner, E | 1 |
| Nelson, WB | 1 |
| House, CM | 1 |
| Dahiya, R | 1 |
| Anderson, CP | 1 |
| Benditt, DG | 1 |
| Zhu, DW | 1 |
| Gheorghiade, M | 1 |
| Thyssen, A | 1 |
| Zolynas, R | 1 |
| Nadar, VK | 1 |
| Greenberg, BH | 1 |
| Mehra, M | 1 |
| Sun, X | 1 |
| Tian, H | 1 |
| Plotnikov, AN | 1 |
| Burton, P | 1 |
| Elsaid, KA | 1 |
| Collins, CM | 1 |
| Alikhan, R | 1 |
| Cohen, AT | 1 |
| Combe, S | 1 |
| Samama, MM | 1 |
| Desjardins, L | 1 |
| Eldor, A | 1 |
| Janbon, C | 1 |
| Leizorovicz, A | 1 |
| Olsson, CG | 1 |
| Turpie, AG | 1 |
| Brophy, DF | 2 |
| Martin, EJ | 2 |
| Gehr, TW | 2 |
| Carr, ME | 2 |
| Best, AM | 1 |
| Wojnicz, R | 1 |
| Nowak, J | 1 |
| Szyguła-Jurkiewicz, B | 1 |
| Wilczek, K | 1 |
| Lekston, A | 1 |
| Trzeciak, P | 1 |
| Nowalany-Kozielska, E | 1 |
| Zembala, M | 1 |
| Wodniecki, J | 1 |
| Poloński, L | 1 |
| Rizos, I | 1 |
| Tsiodras, S | 1 |
| Rigopoulos, AG | 1 |
| Dragomanovits, S | 1 |
| Kalogeropoulos, AS | 1 |
| Papathanasiou, S | 1 |
| Sakadakis, EA | 1 |
| Kremastinos, DT | 1 |
| Braun, C | 1 |
| Schultz, M | 1 |
| Fang, L | 1 |
| Schaub, M | 1 |
| Back, WE | 1 |
| Herr, D | 1 |
| Laux, V | 1 |
| Rohmeiss, P | 1 |
| Schnuelle, P | 1 |
| van der Woude, FJ | 1 |
| Farajdokht, F | 1 |
| Soleimani, M | 1 |
| Mehrpouya, S | 1 |
| Barati, M | 1 |
| Nahavandi, A | 1 |
| Gillespie, MA | 1 |
| Lyle, CA | 1 |
| Goldenberg, NA | 1 |
| Attman, PO | 1 |
| Ottosson, P | 1 |
| Samuelsson, O | 1 |
| Eriksson, UG | 1 |
| Eriksson-Lepkowska, M | 1 |
| Fager, G | 1 |
| Toss, H | 1 |
| Gnarpe, J | 1 |
| Gnarpe, H | 1 |
| Siegbahn, A | 1 |
| Lindahl, B | 1 |
| Wallentin, L | 1 |
| Cummins, D | 1 |
| Segal, H | 1 |
| Hunt, BJ | 1 |
| Awad, R | 1 |
| Maddox, A | 1 |
| Pauwels, R | 1 |
| Devreese, K | 1 |
| Van Biesen, W | 1 |
| Eloot, S | 1 |
| Glorieux, G | 1 |
| Vanholder, R | 1 |
| Dhondt, A | 1 |
3 reviews available for dalteparin and Chronic Illness
| Article | Year |
|---|---|
[Low-molecular weight heparin and acute coronary syndrome: theoretical background and its use in clinical practice].
Topics: Acute Disease; Anticoagulants; Chronic Disease; Clinical Trials as Topic; Coronary Disease; Daltepar | 2001 |
Parnaparin : a review of its use in the management of venous thromboembolism, chronic venous disease and other vascular disorders.
Topics: Anticoagulants; Cardiovascular Diseases; Chronic Disease; Drug Administration Schedule; Fibrinolytic | 2008 |
Updates in pediatric venous thromboembolism.
Topics: Anticoagulants; Child; Chronic Disease; Clinical Trials as Topic; Dalteparin; Fibrinolytic Agents; F | 2015 |
7 trials available for dalteparin and Chronic Illness
| Article | Year |
|---|---|
Low molecular weight heparin improves healing of chronic venous ulcers especially in the elderly.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Chronic Disease; Drug Administration Schedule; | 2015 |
[Chronic pulmonary heart diseases treated by fraxiparin].
Topics: Adult; Aged; Anticoagulants; Antithrombin III; Chronic Disease; Female; Fibrin Fibrinogen Degradatio | 1998 |
Comparison of two low-molecular weight heparins (LMWHs), tinzaparin and bemiparin, during hemodialysis.
Topics: Adult; Blood Coagulation; Chronic Disease; Drug Administration Schedule; Factor Xa; Factor Xa Inhibi | 2005 |
Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombin III; Biomarkers; Chronic Disease; Doubl | 2011 |
Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Chronic Disease; Dose-Response Relationship, Drug; Double-B | 2003 |
Adjunctive therapy with low-molecular-weight heparin in patients with chronic heart failure secondary to dilated cardiomyopathy: one-year follow-up results of the randomized trial.
Topics: Adult; Anticoagulants; Cardiac Output, Low; Cardiomyopathy, Dilated; Cardiovascular Agents; Chronic | 2006 |
Prevention of clot formation during haemodialysis using the direct thrombin inhibitor melagatran in patients with chronic uraemia.
Topics: Adult; Aged; Anticoagulants; Antithrombins; Azetidines; Benzylamines; Chronic Disease; Dalteparin; G | 2005 |
13 other studies available for dalteparin and Chronic Illness
| Article | Year |
|---|---|
Heparin and tranexamic Acid therapy may be effective in treatment-resistant chronic urticaria with elevated d-dimer: a pilot study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Antifibrinolytic Agents; Cetirizine; Chr | 2010 |
[The effect of fraxiparin on thrombocytic-vascular hemostasis in patients with unstable stenocardia].
Topics: Adult; Aged; Angina, Unstable; Blood Platelets; Blood Vessels; Chronic Disease; Drug Evaluation; Dru | 1993 |
[The effect of long-term Fraxiparin treatment on hemostasis in patients with primary pulmonary hypertension].
Topics: Adult; Anticoagulants; Chronic Disease; Drug Evaluation; Drug Therapy, Combination; Female; Hemostas | 1997 |
Continuing warfarin therapy is superior to interrupting warfarin with or without bridging anticoagulation therapy in patients undergoing pacemaker and defibrillator implantation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cardiac Pacing, Artificial; Chronic Disease; Confidence I | 2010 |
Initiative to improve thromboprophylactic enoxaparin exposure in hospitalized patients with renal impairment.
Topics: Acute Disease; Aged; Aged, 80 and over; Anticoagulants; Chronic Disease; Cohort Studies; Creatinine; | 2012 |
Enhanced anticoagulant activity of enoxaparin in patients with ESRD as measured by thrombin generation time.
Topics: Adult; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Chronic Disease; Enoxaparin; Fact | 2004 |
Antifactor Xa activity correlates to thrombin generation time, platelet contractile force and clot elastic modulus following ex vivo enoxaparin exposure in patients with and without renal dysfunction.
Topics: Adult; Anticoagulants; Blood Coagulation Tests; Blood Platelets; Chronic Disease; Dose-Response Rela | 2004 |
Interleukin-2 serum levels variations in recent onset atrial fibrillation are related with cardioversion outcome.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; C-Reactive Protein | 2007 |
Treatment of chronic renal allograft rejection in rats with a low-molecular-weight heparin (reviparin).
Topics: Animals; Anticoagulants; Chronic Disease; Cyclosporine; Graft Rejection; Heparin, Low-Molecular-Weig | 2001 |
The role of hepcidin in chronic mild stress-induced depression.
Topics: Animals; Chronic Disease; Dalteparin; Depression; Hepcidins; Hippocampus; Interleukin-6; Iron; Male; | 2015 |
Increased fibrinogen levels are associated with persistent Chlamydia pneumoniae infection in unstable coronary artery disease.
Topics: Angina, Unstable; Antibodies, Anti-Idiotypic; Anticoagulants; Biomarkers; C-Reactive Protein; Chlamy | 1998 |
Chronic disseminated intravascular coagulation after surgery for abdominal aortic aneurysm: clinical and haemostatic response to dalteparin.
Topics: Aged; Anticoagulants; Antithrombins; Aortic Aneurysm, Abdominal; Chronic Disease; Dalteparin; Dissem | 2001 |
Bedside monitoring of anticoagulation in chronic haemodialysis patients treated with tinzaparin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation; Chronic Disease; Factor Xa Inhibitors; F | 2014 |